| Identification | Back Directory | [Name]
L-Alaninamide,N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-[(2,6-dichlorobenzoyl)oxy]-1-(2-ethoxy-2-oxoethyl)-2-oxopropyl]-(9CI) | [CAS]
161511-45-1 | [Synonyms]
VE 13045
Z-Val-Ala-Asp(OEt)-CH2-DCB
L-Alaninamide,N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-[(2,6-dichlorobenzoyl)oxy]-1-(2-ethoxy-2-oxoethyl)-2-oxopropyl]-(9CI) | [Molecular Formula]
C30H35Cl2N3O9 | [MOL File]
161511-45-1.mol | [Molecular Weight]
652.52 |
| Chemical Properties | Back Directory | [Boiling point ]
861.9±65.0 °C(Predicted) | [density ]
1.299±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
11.05±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2]. | [Biological Activity]
SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2].
SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema[2].SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg[2]. | [in vivo]
SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema[2].
SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg[2].
| [storage]
Store at -20°C | [References]
[1]. Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021 Jun 24;11(1):13208. [2]. P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6. |
|
|